georgie18
4 years ago
KTOV...$4.15...in the P/M...TEL AVIV, Israel, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (the โCompanyโ) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that it has changed its corporate name from Kitov Pharma Ltd. to Purple Biotech Ltd. The name change will be effective for trading purposes on the Tel Aviv Stock Exchange (TASE) and the NASDAQ Capital Market (NASDAQ) as of market open on December 22, 2020. At that time, the Companyโs ordinary shares and American Depositary Shares (ADSs) will begin to trade under the new ticker symbol, โPPBT,โ on the TASE and NASDAQ, respectively. The Companyโs ordinary shares will continue to trade on the TASE and its ADSs will continue to trade on NASDAQ under the ticker symbol โKTOVโ through market close on December 21, 2020. The Companyโs ADSs were assigned a new CUSIP number (74638P109), effective on December 22, 2020, as described above.
georgie18
4 years ago
KTOV...$4.50...in the P/M...https://www.otcmarkets.com/stock/KTOV/news/story?e&id=1716514
TEL AVIV, Israel, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (โKitovโ) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, announced new data supporting the mechanism of action of NT219, a dual inhibitor, novel small molecule targeting IRS1/2 and STAT3 is being presented in a video recorded presentation at the Epigenetics and Metabolism AACR Special Virtual Conference by researchers at Tel-Aviv University. The data was generated as part of the Companyโs collaboration with Professor Ido Wolf, Head of the Oncology Division, Tel Aviv Sourasky Medical Center.